[Hemostatic disorders in the treatment of leukoblastosis with L-asparaginase (crasnitin)].
D000991:Antithrombins / Q000097:blood; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects*; D001792:Blood Platelets / Q000187:drug effects; D005169:Factor VIII / Q000032:analysis; D005176:Factor XIII / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D006470:Hemorrhage / Q000139:chemically induced; D006487:Hemostasis; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D010958:Plasminogen / Q000097:blood; D011516:Prothrombin / Q000097:blood; D011517:Prothrombin Time; D012712:Serum Globulins / Q000032:analysis; D013917:Thrombin / Q000032:analysis; D013997:Time Factors
D000991:Antithrombins; D012712:Serum Globulins; D011516:Prothrombin; D005169:Factor VIII; D005340:Fibrinogen; D010958:Plasminogen; D005176:Factor XIII; D013917:Thrombin; D005341:Fibrinolysin; D001215:Asparaginase
Khemostazni narusheniia pri lechenieto na blastnata levkoza s L-asparaginaza (krasnitin.